As the Director of Preclinical Development at Santero Therapeutics, Bernard Scorneaux plays a pivotal role in advancing the company's mission to combat antibiotic-resistant bacteria through the development of first-in-class antimicrobials. With over 15 years of experience in preclinical and R&D development, Bernard has successfully managed...
As the Director of Preclinical Development at Santero Therapeutics, Bernard Scorneaux plays a pivotal role in advancing the company's mission to combat antibiotic-resistant bacteria through the development of first-in-class antimicrobials. With over 15 years of experience in preclinical and R&D development, Bernard has successfully managed multiple projects that have progressed to clinical phases, showcasing his expertise in drug discovery and project management. His leadership has been instrumental in guiding teams through the complexities of the drug development pipeline, ensuring that innovative therapies are not only conceived but also rigorously tested for efficacy and safety.
At Santero, Bernard is currently spearheading key projects that leverage cutting-edge methodologies, including the design of experiments and in vitro studies, to explore new mechanisms of action against resistant pathogens. His proficiency in GLP (Good Laboratory Practice) ensures that all preclinical studies meet the highest regulatory standards, facilitating a smoother transition to clinical trials. Additionally, his background in veterinary medicine enriches his understanding of antimicrobial applications across species, further enhancing the therapeutic potential of Santero's drug candidates.
Bernard's commitment to advancing human health through innovative treatments is evident in his strategic approach to overcoming the challenges posed by antibiotic resistance. His expertise in high-performance liquid chromatography (HPLC) and other analytical techniques allows for precise characterization of compounds, ensuring that only the most promising candidates move forward in development. As he continues to lead Santero Therapeutics in its groundbreaking endeavors, Bernard remains dedicated to fostering collaboration and driving scientific excellence in the pursuit of effective antimicrobial therapies.
